INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023

Rhea-AI Summary

INVO Bioscience, Inc. (NASDAQ: INVO) to report financial results for its second quarter 2023 on August 14, 2023, after market close. The company will also conduct a conference call at 4:30 pm ET on the same day to review the results, offering interested parties call-in and webcast options for participation.

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET

SARASOTA, Fla., Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023. The Company has scheduled a conference call that same day, Monday, August 14, 2023, at 4:30 pm ET, to review the results.

Second Quarter 2023 Conference Call Details

Date and Time: Monday, August 14, 2023, at 4:30 pm ET

Call-in Information: Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751.

Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ or https://app.webinar.net/y0l43MO6o9Z.

Replay: A teleconference replay of the call will be available through August 21, 2023, at 877-344-7529 or 412-317-0088, replay access code #8863258. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days. 

About INVO Bioscience

We are a healthcare services fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated "INVO Centers" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization ("IVF") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination ("IUI"). For more information, please visit www.invobio.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/invo-to-report-second-quarter-2023-financial-results-on-monday-august-14-2023-301897232.html

SOURCE INVO Bioscience, Inc.

FAQ

When will INVO Bioscience release its financial results for the second quarter of 2023?

INVO Bioscience will release its financial results for the second quarter of 2023 after market close on August 14, 2023.

When is the conference call scheduled for the review of the financial results?

The conference call for the review of the financial results is scheduled for Monday, August 14, 2023, at 4:30 pm ET.

How can interested parties access the conference call?

Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751, or via a live webcast available on the Company's website.

How long will the replay of the conference call be available?

The teleconference replay will be available through August 21, 2023, and the webcast replay will be available for 90 days in the Investor Relations section of the Company's website.